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Abstract 
Introduction. Currently, topicality the problem of diagnosis and treatment of depressive 
disorders (DD) in medical practice is not in doubt. The drugs of choice in the treatment of this 
affective disease are the selective serotonin reuptake inhibitors (SSRIs). One of the best known 
and widely used today of representatives a number of SSRIs is fluoxetine. An example 
perspective way to improve the pharmacotherapy of depression is to combine SSIRs with 
representatives of other groups of drugs. Great interest from this point of view is the hormone of 
pineal gland - melatonin (MT), which is an important element of the non-specific antistress 
system of body. One more potentially significant vector of perfecting therapy is 
searching/development of the new, more potent and fast-acting antidepressants. In this respect, 
the attention of researchers attracts agonist to MT1- and MT2-receptors and antagonist to 5-HT2C-
receptors - valdoxan. Materials and methods. In this study, by means of quantitative pharmaco-
EEG (QPEEG) was performed a comparative evaluation of pharmacological activity of valdoxan, 
fluoxetine and combination of fluoxetine with melaxen during rat's experimental depression (ED) 
and depressive disorder (DD) in patients. Pharmacoeconomic analysis was performed by the 
method of "cost/effectiveness". Results and discussion. It was established that reception of 
valdoxan and combined fluoxetine with melaxen promotes a more rapid normalization of 
bioelectric activity of brain than at fluoxetine usage separately. So, on the EEG at rats with ED 
was registered significant increase of theta-rhythm activity, which dominates in the norm, and at 
patients with DD this regime of pharmacotherapy normalized the distribution of the alpha-rhythm 
and reduced slow-wave activity. Conclusions. Evaluation efficiency of the above regimes of 
pharmacotherapy of depressive frustration showed, that the application of valdoxan, and also 
combination fluoxetine+melaxen favorably affects the course of the disease and contributes to a 
more rapid normalization of bioelectric activity of brain than fluoxetine in isolation, both 
experimentally and clinically. 
Keywords: depression, rats, patients, valdoxan, fluoxetine, melaxen, pharmaco–EEG. 
 
Introduction. Currently, there is a distinct 
increase of the DD in the general population [1] and 
in patients with chronic somatic diseases [2]. 
According to the principles of evidence-based 
medicine group of antidepressants – selective 
serotonin reuptake inhibitors (SSRIs) are considered 
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as standard and must be included in the plan for the 
treatment of affective disorders. SSRIs, as we know, 
have a wide range of pharmacological effects, 
including: anxiolytic, expressed analgetic and 
antipanic. Clinical efficiency of this group of 
antidepressants is proved at treatment of chronic 
pain, bulimia, obesity, alcoholism, obsessive-
compulsive frustration, panic frustration etc. [3, 4]. 
Among the best known and widely used today of 
representatives a number of SSRIs reversible type of 
action is fluoxetine. This drug increases the 
extracellular concentrations of serotonin, slightly 
influences on norepinephrine and dopamine and 
almost not modulates the activity of choline- and 
histamine H1-receptors. This explains the absence 
sedative and cardiotoxic potential of this drug. If we 
compare fluoxetine with antidepressants of other 
groups (three- and heterocyclic), it can be described 
as the drug with a minimum of side-effects, and more 
secure, even at absolute overdose [5]. However, at 
the majority of patients, who use fluoxetine, observed 
anxiety, agitation, sleep disturbances, sexual 
dysfunction [6, 7]. 
One of the most perspective ways to improve the 
pharmacotherapy of depression is to combine SSIRs 
with representatives of other groups of psychotropic 
(and other) drugs. Thus, there is evidence on the joint 
use of antidepressants with antipsychotics in order to 
improve the treatment of psychosis and drug-resistant 
forms of depression [8]. But of much greater interest 
to the combined pharmacotherapy of depression is 
the hormone of pineal gland - melatonin (MT), which 
is an important element of the non-specific antistress 
system of body and control cycle "sleep-wake" [9]. 
But, one more potentially significant vector of 
perfecting of antidepressive therapy is 
searching/development of the new, more potent and 
fast-acting antidepressants including those with 
unique mechanisms of action. In this respect, the 
attention of researchers and practitioners attracts 
valdoxan, whose action is based on the agonism to 
MT1- and MT2-receptors and antagonism to 5-HT2C-
receptors [10]. 
Purpose of the study. 
The main objective of our research was to 
analyze changes of the indices of bioelectric activity 
of brain by means of QPEEG dynamics in rats with 
ED and in patients with ED during treatment by 
modern antidepressants. 
Materials and methods. 
The object of the experimental study were 120 
white outbred male rats weighing 150-180 g (at 
beginning of experiment), which were divided into 5 
groups (2 - control and 3 - experimental) 30 animals 
in each. Control groups were as follows: the intact 
rats (group C) (n=30) and rats, with modelled ED 
(group D) (n=90). Group D was subsequently divided 
into 3 experimental groups, in which animals during 
the experiment had a per os treatment by following 
drugs: fluoxetine in dose of 0.3 mg/kg/day (group F) 
(n=30); valdoxan in dose of 0.5 mg kg/day (group V) 
(n=30); fluoxetine - 0.3 mg/kg/day and melaxen 0.05 
mg/kg/d (group F+M) (n=30). Modeling rat's ED 
included 3 stages: stage 1 (the 1st week) - the animals 
once a day were exposed to a 2-hour immobilization 
in a plastic container; stage 2 (the 2nd week) - once a 
day, for 30 minutes induced water-immersion cold 
stress; stage 3 (3-4 weeks) - was applied 2 above-
stated stress factors. Throughout all 4 weeks of 
experiment the animals were also subjected to 
chronic exposure to light. EEG recording was made 
on the 7th, 14th and 21st days of receiving the drugs. 
According to stereotaxic coordinates to rats of all 
groups to the area of somatosensory cortex (SSC) and 
CA1 region of hippocampus (HC) symmetrically on 
both sides microelectrodes were implanted, and after 
3 days EEG was recorded. Next, the rats of 
experimental groups for 3 weeks of experiment had a 
per os treatment by studied drugs. 
In a clinical study 45 people were included. 
Group D (n=45) consisted of patients with a 
diagnosis of DD moderate; group C (n=17) - 
practically healthy people; group F (n=15) - patients 
treated for 42 days fluoxetine in dose of 20 mg/day 
per os once in the morning after food; group V 
(n=15) - patients treated for 42 days valdoxan in dose 
of 25 mg/day per os once hour before bedtime and, 
finally, group F+M (n=15) - patients treated for 42 
days combination of fluoxetine with melaxen per os 
at doses of 20 mg/day once in the morning after food 
and 3 mg/day once hour before bedtime, respectively. 
The criteria take into account the effectiveness of 
pharmacotherapy EEG data in patients before 
prescribing medication and on the 14th, 28th and 
42th days of treatment. 
Register EEG in experiment and clinical study 
was registered with usage 8-channel encephalograph 
EEGA-21/26 "Encephalan 131-03" ("Medicom-
MTD", Russia), in accordance with the generally 
accepted rules. We analyzed the relative values of 
power (RVP) (%) for delta- (δ-), theta- (θ-), alpha- 
(α-) and beta- (β-) frequency EEG bands. 
Pharmacoeconomic analysis was performed by the 
method of "cost/effectiveness". The outcome of this 
analysis was the cost-effectiveness ratio, calculated by 
the formula: CEA = cost of treatment (RUB.) / RVP 
(%) of α-rhythm in the occipital region. 
Results and discussion. 
During the analysis of indexes EEG rhythms in 
the experimental part of our work it was established 
that for group was characteristic significant 
dominance of θ-rhythm in all leads, its larger activity 
was noted in HC, than in SSC. δ-rhythm was 
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considerably less, and α- and β-rhythms were 
virtually not registered. 
At the ED distribution of power values of EEG 
rhythms in rats changed in such a way that the θ-rhythm 
significantly decreased, and began to dominate the δ--
rhythm. RVP (%) EEG rhythms of rats at reference 
state and at the ED are shown in Table 1. 
Table 1. 
The comparative characteristic of RVP (%) of EEG rhythms of rats 
at reference state and at the ED. 
ELECTRODE LOCALIZATION EEG RHYTHM 
GROUPS OF ANIMALS 
С D 
HC 
δ 22,29±2,71 58,99±4,83** 
θ 60,95±4,06 29,27±3,65** 
α 7,00±0,38 5,61±0,26 
β 9,76±0,38 6,13±0,92 
SSC 
δ 27,43±2,34 52,80±5,02** 
θ 56,84±5,89 35,34±3,39** 
α 6,74±0,29 5,80±0,33 
β 8,99±0,34 6,24±0,36 
Note: *- at p<0.05 as compared to animals of group C; ** - at p<0.01 as compared to animals of group C. 
 
On the 7th day in group F, where rats received 
fluoxetine, change of EEG rhythms consisted in 
reliable decrease δ- and a slight increase in θ-activity 
as compared to indexes at ED. 
At introduction of valdoxan (in group V) 
changes of RVP of EEG rhythms affected mainly δ-
rhythm, which decreased significantly in 2 times in 
the SSC and a little less - in HC, but θ-rhythm, on the 
contrary, progressively increased in both zones 
registration. β-activity has also undergone a change 
in the direction of increasing, exceeding the value of 
C in the SSC of 1.6 times. 
In the study of RVP of EEG rhythms in rats in 
group F+M, there was a significant decrease in the 
level of δ- and a slight increase - θ-range compared to 
the ED. In addition, in both derivations recorded 
increase β-rhythm, which was to prevail over the 
performance of C is almost 2 times (Table 2). 
Table 2. 
The comparative characteristic of RVP (%) of EEG rhythms of rats 
of groups F, V and F+M on the 7th day of introduction. 
ELECTRODE LOCALIZATION 
EEG 
RHYTHM 
GROUPS OF ANIMALS 
F V F+M 
HC 
δ 45,57±3,96**
#
 27,43±2,57
##
 41,48±3,96**
#
 
θ 38,05±3,14**
#
 44,28±3,65**
##
 35,61±1,57**
#
 
α 7,56±0,64 6,94±0,50 7,11±0,77 
β 8,82±0,63 10,45±0,69
#
 13,81±2,04*
##
 
SSC 
δ 43,96±2,84**
#
 23,90±1,82
##
 37,37±2,19*
##
 
θ 40,54±3,50** 42,36±2,77* 36,32±2,13** 
α 5,85±0,52 6,99±0,45 6,79±0,80 
β 8,65±0,42 14,60±3,67*
##
 16,52±3,69**
##
 
Note: *- at p<0.05 as compared to animals of group C; ** - at p<0.01 as compared to animals of group C; 
# 
-
 
at p<0.05 as 
compared to animals of group D; 
# # 
-
 
at p<0.01 as compared to animals of group D. 
 
On the 14th day of observation at rats in group F δ-
rhythm progressively decreases, the θ-rhythm 
increased; β-activity strengthening, more expressed in 
the field of SSC, than in HC. 
At rats to whom entered valdoxan the θ-rhythm 
with excess of its values in all recorded assignments 
(especially - in HC) in comparison with indexes of 
norm dominated. The δ-rhythm was below values of 
group C, and the β-rhythm remained increased in the 
field of  SSC. 
At introduction of a combination of MP in the 
F+M group the δ-rhythm decreased twice in relation 
to indexes at ED, a θ-rhythm, increased, but did not 
reach original values. Power of a β-rhythm increased 
more, than twice in both assignments in comparison 
with the indicators received and at ED, and is normal 
(Table 3). 
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Table 3. 
The comparative characteristic of RVP (%) of EEG rhythms of rats of groups F, V and F+M on the 14th day  
of introduction. 
ELECTRODE LOCALIZATION 
EEG 
RHYTHM 
GROUPS OF ANIMALS 
F V F+M 
HC 
δ 36,11±2,22**## 14,43±3,57*## 30,93±2,01**## 
θ 42,86±3,43**## 68,28±3,65## 49,07±3,75*## 
α 6,51±0,55 6,64±0,23 6,87±0,57 
β 16,20±2,36**## 11,65±0,69# 13,13±2,70*## 
SSC 
δ 34,80±2,00*## 13,90±2,82**## 28,14±2,18## 
θ 39,87±2,33** 63,46±3,71## 47,11±3,91*# 
α 6,26±0,37 5,69±0,68 6,60±0,91 
β 20,79±2,51**# 16,95±3,67*## 17,82±2,86**## 
Note: *- at p<0.05 as compared to animals of group C; ** - at p<0.01 as compared to animals of group C; 
# 
-
 
at p<0.05 as 
compared to animals of group D; 
# # 
-
 
at p<0.01 as compared to animals of group D. 
 
The analysis of the EEG parameters at animals 
in group F for the 21st day of a pharmacotherapy of 
fluoxetine showed that the θ-rhythm was 
synchronized and had the exact distribution, but 
values of its RVP were authentically below norm. In 
the field of group of companies they decreased in 
comparison with indexes at ED by 1,5 (р<0,01), and 
in the field of SSC - by 1,2 (р<0,05). Indexes of RVP 
of a δ-rhythm did not reach norm and remained 
increased: in assignment of group of companies - by 
1,6 times, and in SSC - by 1,2 times, at the same time 
having decreased concerning indexes at ED both in 
group of companies, and in SSC by 1,5 (р<0,01). 
RVP of a β-rhythm in the field of HC obviously 
increased in 2 (р<0,01), and in SSC - by 3 times 
(р<0,01) in comparison with group D, and on 
comparison by group C. The α-rhythm remained 
invariable, and corresponded to values of norm 
(figure 1). 
 
 
 
Figure 1. Distribution of RVP of EEG rhythms of rats for the 21st day of introduction of fluoxetine. 
 
Note to figures 1-3: on an axis of ordinates – RVP (%), on an abscissa axis – groups of rats and an EEG rhythms in SSC and HC; * at 
p<0.05 as compared to animals of group C; ** - at p<0.01 as compared to animals of group C; 
# 
-
 
at p<0.05 as compared to 
animals of group D; 
# # 
-
 
at p<0.01 as compared to animals of group D. 
 
At the rats receiving valdoxan, RVP values and 
θ-and δ-rhythms were restored in the conditions of 
ED much quicker. Low indicators of δ-activity in 
comparison with monitoring in 1,4 - 1,9 (р<0,05) in 
both assignments were noted. The θ-rhythm exceeded 
input datas both in the field of SSC, and in HC for 
16% (р<0,05). Recorded increase in twice RVP of β-
rhythm in SSC (р<0,01) (figure 2). 
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Figure 2. Distribution of RVP of EEG rhythms of rats for the 21st day of introduction of valdoxan. 
 
At animals of the F+M group indexes were 
similar with group F, except minor changes of 
activity of a β-rhythm which increased twice 
(р<0,01) in comparison with norm more narrow for 
the 7th day, and a δ-rhythm which later from the 
beginning of introduction the combination of drugs 
corresponded 14 days to monitoring in the field of 
SSC, but still remained increased by 1,4 times 
(р<0,01) in the field of HC(figure 3). 
 
 
Figure 3. Distribution of RVP of EEG rhythms of rats for the 21st day of introduction of combination  
of fluoxetine with melaxen. 
 
During the clinical study we defined - how 
rhythmic activity of the brain at patients with DD of 
moderate severity and how its parameters are 
influenced by the carried-out pharmacotherapy 
antidepressants changes. 
In the beginning filing of an EEG at healthy 
people of group C and patients with DD was carried 
out (group D). In group C the α-rhythm which was 
registered in an occipital lead and decreased towards 
the frontal departments of a brain dominated. The β-
rhythm was fixed in the frontal area with gradual 
decrease to a nape, and δ-and θ-rhythms were a little 
expressed in all assignments. 
When filing an EEG at patients with DD 
distribution of rhythms significantly changed. The 
dominating place was taken now by a δ-rhythm, 
increase in RVP of a θ-rhythm was also noted, and the 
maximal values of a α-rhythm recorded to the area of a 
forehead, and in all recorded assignments decrease of 
RVP of a β-rhythm  was observed (table 4). 
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Table 4. 
The comparative characteristic of RVP (%) of EEG rhythms at healthy people and patients with a DD. 
ELECTRODE LOCALIZATION EEG RHYTHM 
GROUPS OF PATIENTS 
C D 
 
Occipital area 
δ 9,28±2,94 41,11±5,69** 
θ 3,47±1,55 15,46±3,69** 
α 76,24±5,55 20,70±2,00** 
β 11,65±4,27 24,37±3,98* 
 
Parietal area 
δ 7,36±2,53 37,61±4,68** 
θ 6,17±1,48 16,10±1,52** 
α 59,12±6,87 25,72±3,03** 
β 26,88±2,32 22,19±3,53 
 
Central area 
δ 5,20±2,67 30,53±5,97** 
θ 4,54±1,60 8,49±1,78* 
α 33,06±5,38 46,26±6,09* 
β 57,88±7,49 14,80±3,15** 
 
Frontal area 
δ 6,21±2,61 36,86±4,34** 
θ 4,09±1,47 7,29±1,81* 
α 25,28±3,85 47,68±6,61** 
β 64,90±7,90 8,17±2,08** 
Note: *- at p<0.05 as compared to group C; ** - at p<0.01 as compared to group C. 
 
At the pharmacotherapy of fluoxetine change of 
EEG rhythms concerned α-rhythm, which began to 
dominate in occipital area for the 28th day of treatment 
and was higher in 2,8 (р<0,01) than indexes at a 
depression. For the 42nd day of a pharmacotherapy of 
its RVP remained below input datas in 1,3 (р<0,05). 
The β-rhythm was distributed correctly too, but slightly 
lagged behind norm in the frontal and central 
departments for 28% (р<0,05). the δ-rhythm kept 
authentically high rates of RVP in all recorded 
assignments (р<0,01), and a θ-rhythm, having reached 
background values for the 28th day, remained 
invariable until the end of observation (figure 4). 
 
Figure 4. Distribution of RVP of EEG rhythms at patients for the 42nd day of introduction of fluoxetine. 
Note to figures 4-6: on an axis of ordinates – RVP (%), on an abscissa axis – the field of registration of EEG rhythms; * at p<0.05 as 
compared to group C; ** - at p<0.01 as compared to group C; 
# 
-
 
at p<0.05 as compared group D; 
# # 
-
 
at p<0.01 as compared to group D 
 
Reception of a combination of F+M affected on 
a rhythmicity, almost similar to that one F. At the 
42nd day of a pharmacotherapy α-and β-rhythms did 
not reach initial indicators, and the δ-rhythm 
remained increased ≈ 2,5 - 3 in all assignments in 
comparison with values in group C (figure 5). 
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Figure 5. Distribution of RVP of EEG rhythms at patients for the 42nd day of introduction combination of fluoxetine with melaxen. 
 
The analysis of RVP of an EEG rhythms at the 
patients accepting valdoxan showed that for the 28th 
day the α-rhythm began to correspond to values in 
group C, except for occipital area where indicators of 
its RVP increased only for the 42nd days of a 
pharmacotherapy and exceeded input datas for 14,4% 
(р<0,05). The β-rhythm was not exposed to special 
modulations unlike a δ-rhythm which underwent 
reliable regress: in occipital, parietal and central area- 
by 4,2–3,4 times (p<0,01), and in the frontal area - by 
5,1 times (p<0,01), having also reached the group C 
RVP level in all assignments, and for the 42nd days 
corresponded to input datas. The θ-rhythm reached 
values of norm more narrow for the 14th day. On the 
person the fact that patients with DD of moderate 
severity have an increase and normalization of values 
of fast-wave activity (α-and β-rhythms) in the 
respective areas of filing of an EEG against the 
background of reception In occurs quicker, than 
against the background of F including at a 
combination of F+M (figure 6). 
 
 
Figure 6. Distribution of RVP of EEG rhythms at patients for the 42nd day of valdoxan. 
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At finally, the pharmacoeconomic analysis of 2 
schemes treatment of DD of moderate severity 
(valdoxan and a combination fluoxetine + melaxen) 
by means of the expense/effectiveness method was 
carried out. 
As criterion of effectiveness we accepted a 
difference (Δ) of RVP values (%) of α-rhythm in 
occipital area of patients for the 28th and 42nd days 
of observation in comparison with its indexes at a 
depression. Data on dynamics of it of an EEG index 
in groups of comparison are provided in table 5. 
Table 5 
Dynamics of RVP (%) of α-rhythm in patients comparison groups in the occipital region of the brain  
 
Parameter Observation time Group V Group F+M 
RVP (%) of α-rhythm 
in the occipital area of the brain 
Norm 76,24±5,55 
Depression 20,70±2,00* 
28 days 60,81±8,95 58,86±6,57* 
Δ by 28 days 40,1±6,2* 38,3±4,3* 
42 days 90,29±4,56* 58,28±5,05*# 
Δ by 42 days 69,6±5,3* 37,6±3,9*# 
Note: * - at p<0.05 as compared to original value in this group; # - at p<0.05 as compared to similar value in group V. 
 
Following the results of processing of results it 
is possible to conclude that the ratio of cost 28 a day 
course of treatment In to its influence on an indicator 
of RVP of a α-rhythm exceeds F+M combination, 
that at application, by 2,2, at the same time this 
rhythm in both groups does not reach even original 
values. However, for the 42nd days of a 
pharmacotherapy this difference became not the so 
considerable and in group V exceeded the 
corresponding indicator of the F+M group for 32,5% 
(i.e. was most of all by 1,4) (figure 7). 
 
Figure 7. Cost-effectiveness of pharmacotherapy course at patients surveyed groups on RVP of a α-rhythm of the brain. 
 
Note: on an axis of ordinates – the drug cost per course of treatment (rub.) / RVP (%) α-rhythm on the 28th and 42th days of observation. 
On an abscissa axis – the period of observation. 
 
Summary. 
According to results of the clinical and 
experimental study of changes in the bioelectric 
activity of the brain by means of QPEEG against the 
background of antidepressant use can be concluded 
that the low values of θ-rhythm, and also increase δ-
and β-activities of brain groups of rats, who received 
fluoxetine separately or in a combination with 
melaxen are bound, probably to the presence of this 
antidepressant anxiogenic effects. The combination 
of F+M has a similar effect on EEG rhythms in rats 
with the only difference that the enhancement of β-
activity was observed on the first week of 
introduction of the studied drugs. This, in our 
opinion, may be associated with the ability melaxen 
has modulatory effects on subcortical structures of 
the brain [11]. 
In turn, valdoxan, not only has a modulating 
effect on θ-activity detected in all leads, but also 
reduces the δ-rate increase and β-rate, especially in 
the SSC. It can be assumed that such changes are 
associated with a unique mechanism of action of 
valdoxan, which distinguishes it from other 
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antidepressants, and, above all, its activating effect 
on MT1-and MT2 – melatonin receptors. 
The analysis of RVP of EEG rhythms at patients 
showed that the main role in modulation of rhythmic 
activity of a brain at patients of groups F and F+M is 
played by fluoxetine which, though promotes the 
exact distribution of a α-rhythm, nevertheless does 
not allow to be restored to it fully. The same can be 
told also about β-activity. This drug also promotes 
preservation of the increased δ-rhythm power in all 
recorded assignments, that correlates with 
conclusions of other authors [12, 13]. 
Based on the above it can be concluded that at 
pharmacotherapy at valdoxan the rhythmic activity of 
a brain is characterized by much more rapid positive 
dynamics of indexes of an EEG from all carried-out 
treatment options that is explained by the unique 
mechanism of action of this drug and, in particular, 
its melatonin-mimetic potential. It is important that 
unlike the tricyclic antidepressants, SSIRs and 
inhibitors of MAO valdoxan, according to literature, 
does not influence serotonin level in the brain [14]. 
Some importance in realizing the effects of the 
arrangements may also have antagonism in relation to 
5-HT2c-reseptors of serotonin and increased 
catecholamine (dopamine and norepinephrine) in the 
frontal cerebral cortex [15]. 
Thus, summarizing the received results, we can 
say that the application of a valdoxan, and also 
combination fluoxetine+melaxen at treatment of 
depressive frustration of moderate severity, favorably 
affects the course of the disease and contributes to a 
more rapid normalization of bioelectric activity of 
brain than fluoxetine in isolation. 
Conclusions. 
1. Long-term usage of valdoxan in contrast to 
the fluoxetine and combination of fluoxetine with 
melaxen helps to normalize the distribution of EEG 
rhythms in rats with ED, as evidenced by an increase 
in RVP of θ-rhythm of 16% in the HC and SSC and 
increase in RVP of β-rhythm of 2 times in the SSC. 
2. QEEG comparative analysis of the results 
shows that the most favorable effect on the rhythmic 
brain activity in patients with DD as compared to 
other circuits has valdoxan therapy, what confirmed, 
first of all, in the increase of 2.9 times (as compared 
to the depression) and normalization RVP of α-
rhythm EEG already on the 28th day of treatment. 
3. By means of pharmacoeconomic analysis was 
showed that as compared to combination 
fluoxetine+melaxen for usage valdoxan characterized 
more favorable values of the coefficient 
"cost/effectiveness" exceeding those of fluoxetine with 
melaxen by 32.5% in terms of impact on the bioelectric 
activity of the brain at patients with depression. 
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